NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
March 4, 2008 • Volume 5 / Number 5 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
ALTTO Trial Seeks to Define Best Therapy for HER2 Breast Cancer

Cancer Research Highlights
Cancer Risk Persists After Ending Hormone Therapy

Hormone Therapy Interferes with Breast Cancer Detection

Study Confirms Clot, Mortality Risks with Anemia Drugs

Sentinel Node Dissection Safe in Early Vulvar Cancer Treatment

Smoking Threatens Pregnant Women in Developing Countries

Director's Update
Keeping Recent Mortality Figures in Perspective

Funding Opportunities

Special Report
Tiny Nodules, Big Dilemma

FDA Update
Bevacizumab Approved for Metastatic Breast Cancer

Featured Clinical Trial
Continuing Bevacizumab Therapy for Metastatic Colorectal Cancer

Notes
NIH Director to Testify Before Appropriations Subcommittee

BSA Meeting Held

Special Issue on Childhood Cancers

Cancer Center Profile
Lombardi Comprehensive Cancer Center

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Funding Opportunities Funding Opportunities

Following are newly released NCI research funding opportunities:

Tumor Stem Cells in Cancer Biology, Prevention, and Therapy
Announcement Number: RFA-CA-08-019

Letter of Intent Receipt Date: April 12, 2008.
Application Receipt Date: May 12, 2008.

This funding opportunity will use the R01 award mechanism. For more information, see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3857. Inquiries: Dr. R. Allan Mufson - mufsonr@mail.nih.gov.

Comparative Systems Genetics of Cancer
Announcement Number: RFA-CA-08-017

Letter of Intent Receipt Date: April 14, 2008.
Application Receipt Date: May 14, 2008.

This funding opportunity will use the R01 award mechanism. For more information, see http://researchportfolio.cancer.gov/initiativedetail.jsp?InitiativeID=3855. Inquiries: Dr. Cheryl L. Marks - marksc@mail.nih.gov; Dr. Mukesh Verma - vermam@mail.nih.gov.

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov